Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.

RET gene fusions are recurrent oncogenes identified in thyroid and lung carcinomas. Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clinical trials. Here we evaluated lenvatinib in RET gene fusion-driven preclinical models. In cellular assays, lenvatinib inhibited auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET. Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells. These results demonstrate that lenvatinib can exert antitumor activity against RET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.

[1]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[2]  S. Ou.  Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond , 2011, Drug design, development and therapy.

[3]  M. Santoro,et al.  BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.

[4]  M. Schlumberger,et al.  A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Andresen,et al.  A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). , 2012 .

[6]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[7]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[8]  Lu Wang,et al.  Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.

[9]  Roman K. Thomas,et al.  Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants , 2012, Clinical Cancer Research.

[10]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[11]  S. Jhiang.  The RET proto-oncogene in human cancers , 2000, Oncogene.

[12]  Y. Funahashi,et al.  Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase , 2008, Clinical Cancer Research.

[13]  G. Fontanini,et al.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. , 2002, Cancer research.

[14]  M. Santoro,et al.  RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. , 2006, European journal of endocrinology.

[15]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[16]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[17]  S. Aebi,et al.  A patient with lung adenocarcinoma and RET fusion treated with vandetanib. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  T. Sugimura,et al.  cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. , 1990, Biochemical and biophysical research communications.

[19]  H. Ueno,et al.  Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results. , 2013 .

[20]  J. Wanders,et al.  A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours , 2012, British Journal of Cancer.

[21]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[22]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[23]  C. Deswarte,et al.  RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation , 2012, Leukemia.

[24]  L. Raez,et al.  Emerging role of multikinase inhibitors for refractory thyroid cancer , 2012, Biologics : targets & therapy.

[25]  Hiroyuki Aburatani,et al.  Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Seungbok Lee,et al.  A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.